4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-005748
PRESIDENT AND CEO sold 12,000 shares at an average $16.89 ($202,653)
- PRESIDENT AND CEO acquired 12,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Kintz Samuel · PRESIDENT AND CEO
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-02-26 | Exercise or conversion : show line 1 in the form 10b5-1 | +12,000 | $1.12 | $13,440 | 12,000 | D |
| 2024-02-26 | Sale : show line 2 in the form 10b5-1 | −7,624 | $16.69 | $127,219 | 4,376 | D |
| 2024-02-26 | Sale : show line 3 in the form 10b5-1 | −4,376 | $17.24 | $75,435 | 0 | D |
| Open-market sales · 12,000 sh · avg $16.89 · $202,653 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-02-26 | Exercise or conversion : show line 4 in the form 10b5-1 Stock Option (right to buy) | −12,000 | 272,550 | D |
Loading xslF345X05/form4-02282024_100201.xml…